Lots of inconsistency here. $22 million raised at 24c (32c when...

Lots of inconsistency here. $22 million raised at 24c (32c when option converted). Both of those prices well above the 12 month Vwap. This premium to Vwap reduced dilution.

Retail not happy that instos and 708s got the first bite of the cherry, and then to teach MD a lesson didnt take entitlement. Talk about cutting off nose to spite the face.

Price is dropping because of over hang from retail not putting up cash to get the trial funded. And because the worlds biotech sector has been sold down.

So now retail whine that the price has dropped. And blame MD. And thats after he raised a potential $44 million at 32c (if/when options are converted).

The top 20 only hold 30% of the company. Instos even less. The large retail holding put a torpedo into the CR.

The science hasnt changed. Funding will be found. The trial will happen. If the drug works as it did in the last trial approval will be given.

I am buying at this share price. I also took extra of the entitlement.

Futility in 15 plus months. Exciting times ahead.